Journal of Literature Pharmacy Sciences

Tip 2 Diabetes Mellitus Tedavisinde Dipeptidil Peptidaz İnhibitörleri ve Transdermal Yaklaşım: Geleneksel Derleme
Dipeptidyl Peptidase Inhibitors and Transdermal Approach in Type 2 Diabetes Mellitus Treatment: Traditional Review
Zeynep CEMEKa , Sevinç ŞAHBAZb
aMarmara Üniversitesi Sağlık Bilimleri Enstitüsü, Farmasötik Teknoloji AD, İstanbul, Türkiye
bMarmara Üniversitesi Eczacılık Fakültesi, Farmasötik Teknoloji AD, İstanbul, Türkiye
J Lit Pharm Sci. 2024;13(3):177-88
doi: 10.5336/pharmsci.2024-102321
Article Language: TR
Full Text
ÖZET
 Tip 2 diabetes mellitus, dünya genelinde yaygın olarak görülen dejeneratif ancak kontrol altında tutulabilir önemli bir sağlık sorunu olup, yaşam boyu sürecek tedavi yönetimi gerektirmektedir. Yaşam kalitesini en fazla etkileyen kronik hastalıklardan biri olarak kabul edilmekte ve ciddi bir tıbbi, sosyal ve ekonomik tehdit oluşturmaktadır. Geleneksel oral antidiyabetik ilaçlar hem biyoyararlanım ve dozaj yönetimi açısından hem de hasta uyuncu ve tedavinin etkililiği açısından dezavantajlara sahip olabilmektedir. Bu bağlamda geliştirilmekte olan transdermal ilaç formülasyonları, diyabet tedavisinde yeni bir perspektif sunmaktadır. İnkretin bazlı etki gösteren dipeptidil peptidaz (DPP)- 4 enzim inhibitörleri; sitagliptin, saksagliptin, linagliptin, alogliptin ve vildagliptin olarak sıralanabilir. DPP-4 inhibitörleri, glukagon benzeri peptid-1 (GLP-1) ve gastrik inhibitör polipeptid (GIP) gibi endojen inkretinlerin konsantrasyonunu ve aktivitesini artırıp bu hormonların DPP-4 tarafından proteolitik parçalanmasını engelleyerek etki gösterir ve bunları aktif olmayan moleküllere dönüştürür. Aktif GLP-1 ve GIP seviyesindeki artış, glukozla uyarılmış insülin salgısını potansiyalize eder. DPP-4 inhibitörlerinin oral uygulamalarının sınırlamaları, transdermal formülasyonların geliştirilmesine zemin hazırlamıştır. Bu derlemenin amacı, DPP-4 inhibitörleri kullanılarak hazırlanan transdermal formülasyonlara odaklanarak, hazırlanan transdermal formülasyonların diyabet tedavisindeki potansiyel avantajlarını incelemektir. DPP-4 inhibitörleri kullanılarak hazırlanan transdermal formülasyonların formülasyon ajanları ve metodu, salım profilleri, oral kullanıma kıyasla sağladıkları avantajlar detaylı bir şekilde ele alınmış. DPP-4 inhibitörlerinin transdermal kullanımına ilişkin son gelişmeler incelenerek gelecekteki potansiyel araştırma alanları vurgulanmıştır.

Anahtar Kelimeler: Transdermal yama; dipeptidil-peptidaz IV inhibitörleri; diabetes mellitus; Tip 2
ABSTRACT
 Type 2 diabetes mellitus is a degenerative but controllable worldwide health issue, requiring lifelong treatment management. It is considered one of the chronic diseases that most significantly affects quality of life and poses a serious medical, social and economic threat. Traditional oral antidiabetic drugs may have disadvantages in terms of bioavailability and dosage management, as well as patient compliance and effectiveness of treatment. In this context, developing transdermal drug formulations offers a new perspective in diabetes treatment. Incretin based dipeptidyl peptidase (DPP)-4 enzyme inhibitors can be listed as sitagliptin, saxagliptin, linagliptin, alogliptin and vildagliptin. DPP-4 inhibitors increase the concentration and activity of endogenous incretins such as glucagonlike peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP), inhibiting their proteolytic breakdown by DPP-4 and converting them into active molecules. Increased levels of active GLP-1 and GIP potentiate glucose-stimulated insulin secretion. The limitations of oral administration of DPP-4 inhibitors have paved the way for the development of transdermal formulations. The aim of this review is to focus on transdermal formulations prepared using DPP-4 inhibitors and examine the potential advantages of these formulations in diabetes treatment. Formulation agents and methods, release profiles and advantages of transdermal formulations prepared using DPP-4 inhibitors compared to oral use are discussed in detail. Recent developments regarding the transdermal use of DPP-4 inhibitors are reviewed and potential areas for future research are highlighted.

Keywords: Transdermal patch; dipeptidyl-peptidase IV inhibitors; diabetes mellitus; Type 2
REFERENCES:
  1. Zhao M, Xie Y, Gao W, Li C, Ye Q, Li Y. Diabetes mellitus promotes susceptibility to periodontitis-novel insight into the molecular mechanisms. Front Endocrinol (Lausanne). 2023;14:1192625. [Crossref]  [PubMed]  [PMC] 
  2. Centers for Disease (CDC) and Prevention. National Diabetes Statistics Report [Internet]. 2023 [cited: 20 November 2024]. Available from: [Link] 
  3. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271-81. [Crossref]  [PubMed] 
  4. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. Erratum in: Diabetes Res Clin Pract. 2023;204:110945. [Crossref]  [PubMed]  [PMC] 
  5. IDF Diabetes Mellitus [Internet]. ©2022 International Diabetes Federation [Cited: October 21, 2023]. Available from: [Link] 
  6. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4-14. [Crossref]  [PubMed] 
  7. Murea M, Ma L, Freedman BI. Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. Rev Diabet Stud. 2012;9(1):6-22. [Crossref]  [PubMed]  [PMC] 
  8. Obradovic M, Milovanovic ES, Gluvic Z, Gojobori T, Essck M, Esma I. Diabetes and treatments. Faintuch J, Faintuch S, eds. Obesity and Diabetes: Scientific Advances and Best Practice. 2nd ed. Cham: Springer International Publishing; 2020. p.705-17. [Crossref] 
  9. Çelik Ö, Rustamova N. Gestasyonel diyabet tanı ve tedavisi [Diagnosis and treatment of gestational diabetes]. Klinik Tıp Bilimleri Dergisi. 2019;7(3):24-7. [Link] 
  10. Suryasa IW, Rodríguez-Gámez M, Koldoris T. Health and treatment of diabetes mellitus. Int J Health Sci (Qassim). Universidad Tecnica de Manabi. 2021;5(1):I-V. [Crossref] 
  11. Fang M, Wang D, Coresh J, Selvin E. Trends in diabetes treatment and control in U.S. Adults, 1999-2018. N Engl J Med. 2021;384(23):2219-28. [Crossref]  [PubMed]  [PMC] 
  12. Galiero R, Caturano A, Vetrano E, Monda M, Marfella R, Sardu C, et al. Precision Medicine in Type 2 Diabetes Mellitus: Utility and Limitations. Diabetes Metab Syndr Obes. 2023;16:3669-89. [Crossref]  [PubMed]  [PMC] 
  13. Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by the American Association Of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2020 Executive Summary. Endocr Pract. 2020;26(1):107-139. [Crossref]  [PubMed] 
  14. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al, on behalf of the American Diabetes Association. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S41-S8. Erratum in: Diabetes Care. 2023;46(9):1716-7. [Crossref]  [PubMed]  [PMC] 
  15. American Diabetes Association. 5. Lifestyle Management: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S46-S60. [Crossref]  [PubMed] 
  16. Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: a review on recent drug based therapeutics. Biomed Pharmacother. 2020;131:110708. [Crossref]  [PubMed] 
  17. Aggarwal N, Singla A, Mathieu C, Montanya E, Pfeiffer AFH, Johnsson E, et al. Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(2):463-7. [Crossref]  [PubMed]  [PMC] 
  18. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103(6):491-7. [Crossref]  [PubMed] 
  19. Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, et al; Diabetes Prevention Program Research Group. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754-61. [Crossref]  [PubMed]  [PMC] 
  20. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461-98. Erratum in: Diabetologia. 2019;62(5):873. [Crossref]  [PubMed] 
  21. Lalau JD, Kajbaf F, Bennis Y, Hurtel-Lemaire AS, Belpaire F, De Broe ME. Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care. 2018;41(3):547-53. [Crossref]  [PubMed] 
  22. Zhang XL, Zhu QQ, Chen YH, Li XL, Chen F, Huang JA, et al. Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 ınhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis. J Am Heart Assoc. 2018;7(2):e007165. [Crossref]  [PubMed]  [PMC] 
  23. Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. 2018;61(10):2118-25. [Crossref]  [PubMed] 
  24. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-57. [Crossref]  [PubMed] 
  25. Pantelis A. Sarafidis, Apostolos Tsapas. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2016;374(11):1092-4. [Crossref] 
  26. Yabe D, Shiki K, Homma G, Meinicke T, Ogura Y, Seino Y; EMPA-ELDERLY Investigators. Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY). Diabetes Obes Metab. 2023;25(12):3538-48. [Crossref]  [PubMed] 
  27. Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol. 2016;12(10):566-92. [Crossref]  [PubMed] 
  28. Caruso I, Di Gioia L, Di Molfetta S, Cignarelli A, Palmer SC, Natale P, et al. Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. EClinicalMedicine. 2023;64:102181. [Crossref]  [PubMed]  [PMC] 
  29. Davies TF. A Case-Based Guide to Clinical Endocrinology. 3rd ed. New York: Springer International Publishing; 2022. [Crossref] 
  30. Salmanoğlu M. Tip 2 diyabetin oral antidiyabetik ilaçlarla tedavisi [Type 2 diabetes treatment with oral antidiabetic drugs]. Klinik Tıp Bilimleri Dergisi. 2019;7(3):20-3. [Link] 
  31. Khunti K, Chatterjee S, Gerstein HC, Zoungas S, Davies MJ. Do sulphonylureas still have a place in clinical practice? Lancet Diabetes Endocrinol. 2018;6(10):821-32. [Crossref]  [PubMed] 
  32. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106-18. [Crossref]  [PubMed] 
  33. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem. 2001;70:341-67. [Crossref]  [PubMed] 
  34. Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O, Undavalli C, et al. Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(2):363-70. [Crossref]  [PubMed]  [PMC] 
  35. Younk LM, Mikeladze M, Davis SN. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother. 2011;12(9):1439-51. [Crossref]  [PubMed] 
  36. Dahlén AD, Dashi G, Maslov I, Attwood MM, Jonsson J, Trukhan V, et al. Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales. Front Pharmacol. 2022;12:807548. [Crossref]  [PubMed]  [PMC] 
  37. Sesti G, Avogaro A, Belcastro S, Bonora BM, Croci M, Daniele G, et al. Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetol. 2019;56(6):605-17. [Crossref]  [PubMed] 
  38. Yamamoto-Honda R, Takahashi Y, Mori Y, Yamashita S, Yoshida Y, Kawazu S, et al. Changes in antidiabetic drug prescription and glycemic control trends in elderly patients with Type 2 Diabetes Mellitus from 2005-2013: An Analysis of the National Center Diabetes Database (NCDD-03). Intern Med. 2018;57(9):1229-40. [Crossref]  [PubMed]  [PMC] 
  39. Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol. 2021;9(8):525-44. [Crossref]  [PubMed] 
  40. Alkilani AZ, McCrudden MT, Donnelly RF. Transdermal Drug Delivery: Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the stratum corneum. Pharmaceutics. 2015;7(4):438-70. [Crossref]  [PubMed]  [PMC] 
  41. Ramadon D, McCrudden MTC, Courtenay AJ, Donnelly RF. Enhancement strategies for transdermal drug delivery systems: current trends and applications. Drug Deliv Transl Res. 2022;12(4):758-91. [Crossref]  [PubMed]  [PMC] 
  42. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci. 2001;14(2):101-14. [Crossref]  [PubMed] 
  43. Haque T, Talukder MMU. Chemical Enhancer: A Simplistic Way to Modulate Barrier Function of the Stratum Corneum. Adv Pharm Bull. 2018;8(2):169-79. [Crossref]  [PubMed]  [PMC] 
  44. Barbero AM, Frasch HF. Transcellular route of diffusion through stratum corneum: results from finite element models. J Pharm Sci. 2006;95(10):2186-94. [Crossref]  [PubMed] 
  45. Hamid OA, Yassir Albazzaz F, Khalid Dhahir R. Formulation and characterization of chitosan nanoparticles to enhance transdermal delivery of cinnarizine. J. Excipients and Food Chem. 2023;14(3):71-84. [Link] 
  46. Saihood WA, Abbas HK. Preparation and Evaluation of Hydrogel Containing Prednisolone Nanoparticles. Al Mustansiriyah Journal of Pharmaceutical Sciences; 2023;24(3):463-76. [Crossref] 
  47. Kandalkar A, Jawarkar S, Dhole R, Chachda N, Patel A, Wagh H, et al. Formulation and development of transdermal patches of glibenclamide and comparative effect of various herbal extracts on ex vivo release. Journal of Advanced Zoology. 2023;44(S1):943-55. [Link] 
  48. Kadam A, Deshmukh O, Sagar P. A brief overview on formulation and evaluation of transdermal patches of aceclofenac. Journal of Modernization in Engineering. 2023;5(3):1603-10. [Link] 
  49. Rezky Aulia N, Paramitha Dwi Putri A, Anandha Pratama F, Arnita Putri Abdullah D, Shaa Azzahra K, Dian Permana A, et al. Implantable Trilayer Microneedle Transdermal Delivery System to Enhance Bioavailability and Brain Delivery of Rivastigmine for Alzheimer Treatment: a Proof-of-concept Study. Research Square. 2023. [Crossref] 
  50. Albassam NY, Kassab HJ. Diacerein loaded novasome for transdermal delivery: prepartion, in-vitro characterization and factors affecting formulation. Iraqi Journal of Pharmaceutical Sciences. 2023;32(Suppl.):214-24. [Crossref] 
  51. Bhattacharyya S, Johl S. Novel deformable vesicle for the transdermal delivery of terbinafine hydrochloride-formulation and cytotoxic evaluation. Ind. J. Pharm. Edu. Res. 2024;58(2):460-9. [Crossref] 
  52. Migdadi EM, Courtenay AJ, Tekko IA, McCrudden MTC, Kearney MC, McAlister E, McCarthy HO, Donnelly RF. Hydrogel-forming microneedles enhance transdermal delivery of metformin hydrochloride. J Control Release. 2018;285:142-151. [Crossref]  [PubMed]  [PMC] 
  53. Mutalik S, Udupa N, Kumar S, Agarwal S, Subramanian G, Ranjith AK. Glipizide matrix transdermal systems for diabetes mellitus: preparation, in vitro and preclinical studies. Life Sci. 2006;79(16):1568-77. [Crossref]  [PubMed] 
  54. Mohanty D, Gilani SJ, Zafar A, Imam SS, Kumar LA, Ahmed MM, et al. Formulation and Optimization of Alogliptin-Loaded Polymeric Nanoparticles: In Vitro to In Vivo Assessment. Molecules. 2022;27(14):4470. [Crossref]  [PubMed]  [PMC] 
  55. Prajapati ST, Patel CG, Patel CN. Formulation and evaluation of transdermal patch of repaglinide. ISRN Pharm. 2011;2011:651909. [Crossref]  [PubMed]  [PMC] 
  56. Das B, Nayak AK, Mallick S. Thyme Oil-Containing Fluconazole-Loaded Transferosomal Bigel for Transdermal Delivery. AAPS PharmSciTech. 2023;24(8):240. [Crossref]  [PubMed] 
  57. Magnano GC, Quadri M, Palazzo E, Lotti R, Loschi F, Dall'Acqua S, et al. 3D human foreskin model for testing topical formulations of sildenafil citrate. Int J Pharm. 2024;649:123612. [Crossref]  [PubMed] 
  58. Alfehaid FS, Nair AB, Shah H, Aldhubiab B, Shah J, Mewada V, et al. Enhanced transdermal delivery of apremilast loaded ethosomes: Optimization, characterization and in vivo evaluation. J Drug Deliv Sci Technol. 2024;91:105211. [Crossref] 
  59. Bediz Olcer A, Gonul N. Derinin anatomik yapısı ve fizyolojisi [Percutaneous absorption and factors influencing percutaneous absorption]. J Fac Pharm. 2002;31(1):33-49. [Link] 
  60. Namdeo R, Kumar Patel M, Manigauha A, Pandey A. Formulation and evaluation of transdermal patch of vildagliptin. Int J Ind Herbs Drugs. 2019. [Link] 
  61. Jd G, Colón S, Gray D, Overton B, Wang B. Design and development of a novel sitagliptin-loaded transdermal patch for diabetes treatment. SM J Eng Sci. 2017;1(1):1003. [Link] 
  62. Mehta P, Kajal Sharama M, Patel A. Development and characterization of transdermal drug delivery for enhancement of bioavailability of linagliptin. J P Sci. 2022;2022(7):428-35. [Link] 
  63. Solanke PN, Ambekar AW, Chemate S. Formulation, development and characterization of transdermal drug delivery system for antidiabetic drug. Asian J Pharm Pharmacol. 2018;4(5):668-72. [Crossref] 
  64. Chaudhari PM, Paithankar AV. Formulation optimization and evaluation of transdermal patch of vildagliptin for treatment of diabetes mellitus. Journal of Creative Research Thoughts. 2020;8(3):1713-22. [Link] 
  65. Varma Shukla K, Swamy M, Pathak R. Formulation, development and characterization of transdermal patches of sitagliptin phosphate. Journal of Drug Delivery and Therapeutics. 2019;9(s):408-13. [Crossref] 
  66. Pal R, Mujahid M, Ahmad S. Formulation development and in-vitro evaluation of linagliptin transdermal patch using permeability enhancer. Int J Pharm Sci Rev Res. 2023;82(1):19-28. [Crossref] 
  67. Nair AB, Kumria R, Al-Dhubiab BE, Attimarad M, Harsha S. Development of transdermal delivery system of vildagliptin and its comparison with oral therapy. Indian Journal of Pharmaceutical Education and Research. Association of Pharmaceutical Teachers of India; 2016;50(1):130-7. [Crossref] 
  68. Raja K, Gupta N. Comparative study of sitagliptin phosphate, glimepiride and gliclazide for their safety and efficacy ın diabetes. International Journal of Research in Medical and Basic Sciences. 2020;6(2):6-11. [Link] 
  69. By S, Vignesh R, Senthil Prabhu R, Pharm M. Formulation And Evaluation Of Sitagliptin Phosphate Loaded Transdermal Microspheres Gel. 2018. [Link] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com